SINGAPORE (Dec 29): Japan's Chugai Pharmaceutical is planning to invest some 25 billion yen ($296 million) in a Singapore R&D centre for biopharmaceuticals by 2021, according to Nikkei Asian Review.

Chugai Pharmaceutical intends to expand development of therapeutic antibodies at Chugai Pharmabody Research which will sift through tens of thousands of candidate antibodies to discover the select few fit for commercial use.

The Singapore lab will also invest in automation and artificial intelligence to make the sifting process more efficient.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook